Enovis Corporation/$ENOV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Enovis Corporation
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
- Ticker
- $ENOV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 7,802
- Headquarters
- Lewisville, United States
- Website
- www.enovis.com
ENOV Metrics
BasicAdvanced
$1.1B
-
-$19.22
1.48
-
Price and volume
Market cap
$1.1B
Beta
1.48
52-week high
$34.28
52-week low
$16.70
Average daily volume
2M
Financial strength
Current ratio
1.985
Quick ratio
0.742
Long term debt to equity
0.883
Total debt to equity
0.926
Interest coverage (TTM)
1.07%
Profitability
EBITDA (TTM)
379.792
Gross margin (TTM)
61.32%
Net profit margin (TTM)
-47.97%
Operating margin (TTM)
3.66%
Effective tax rate (TTM)
-2.88%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
1.20%
Return on equity (TTM)
-54.14%
Valuation
Price to revenue (TTM)
0.455
Price to book
0.71
Price to tangible book (TTM)
-2.75
Price to free cash flow (TTM)
16.432
Free cash flow yield (TTM)
6.09%
Free cash flow per share (TTM)
1.111
Growth
Revenue change (TTM)
4.89%
Earnings per share change (TTM)
30.94%
3-year revenue growth (CAGR)
12.17%
10-year revenue growth (CAGR)
-4.49%
3-year earnings per share growth (CAGR)
95.79%
10-year earnings per share growth (CAGR)
20.39%
What the Analysts think about ENOV
Analyst ratings (Buy, Hold, Sell) for Enovis Corporation stock.
Analyst projections of the future price of Enovis Corporation stock.
Bulls say / Bears say
Enovis delivered 5% organic growth in Q2, led by 6% growth in Reconstructive, while US hips and knees grew 8%. Management reaffirmed its 2026 targets of 4–6% organic growth and $425–435 million of adjusted EBITDA, suggesting the recovery remains on track. (Last10K, StockAnalysis)
Profitability and cash generation are improving: Q2 adjusted EBITDA margin rose to 17.9%, adjusted EPS increased 14% year on year, and free cash flow improved by $27 million to $31 million. First-half free cash flow turned slightly positive, giving Enovis a route to reduce leverage and fund growth. (StockAnalysis, Last10K)
The product pipeline could support further share gains. Nebula is winning new instrument placements from competitors, ARVIS has entered full US commercial launch, and the planned eCential acquisition adds robotic surgery capabilities to Enovis’s ASTRA platform. (StockAnalysis, MarketChameleon)
The second half is increasingly dependent on a strong fourth quarter. Management expects unusually heavy third-quarter seasonality because of Western European conditions and Middle East disruption, while inflation is expected to create a roughly $10 million full-year headwind. (StockAnalysis, MassDevice)
The balance sheet leaves limited room for execution mistakes. Enovis had about $1.3 billion of debt and 3.1 times trailing EBITDA leverage, while the eCential deal requires roughly €176 million of cash plus potential earn-outs and will require extra investment before its planned 2028–29 launches. (Last10K, MarketChameleon)
Growth remains uneven and statutory earnings are still weak. Prevention & Recovery sales fell 1% on a reported basis in Q2, while Enovis recorded a small GAAP net loss, leaving investors reliant on Reconstructive momentum and adjusted measures until the recovery broadens. (Last10K, TradingKey)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.
ENOV Financial Performance
Revenues and expenses
ENOV Earnings Performance
Company profitability
Upcoming events
No upcoming events
ENOV News
AllArticlesVideos
Funds containing ENOV
AllUSDGBPEUR
Fund name | Fund size | $ENOV weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.06% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.